Washington Trust’s Apyx Medical APYX Stock Holding History

Washington Trust’s Portfolio APYX Stock Details APYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200	Closed	-$468	–	953
2022 Q4	$468	Hold	200	–	–	﹤0.01%	940
2022 Q3	$1K	Buy	+200	New	+$1.43K	﹤0.01%	830

Other funds holding APYX

Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Washington Trust's APYX Position: Q1 2023 in Review

Washington Trust sold out of Apyx Medical (APYX) in Q1 2023, closing a stake of 200 shares — an estimated $468 sold.

Washington Trust first reported a position in APYX in Q3 2022 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 55 funds tracked by Wall St. Rank hold APYX as of Q1 2023.

Washington Trust reported no remaining Apyx Medical position as of Q1 2023 after selling out during the quarter.
Washington Trust sold 200 Apyx Medical shares in Q1 2023, an estimated $468.
Washington Trust first reported a position in Apyx Medical in Q3 2022 and held it in 2 quarters.
Washington Trust's Apyx Medical position peaked at $1K in Q3 2022.
55 funds tracked by Wall St. Rank held Apyx Medical as of Q1 2023.

Based on Washington Trust's 13F filing for Q1 2023, filed 4 May 2023.